Newest
BETR ▼ sold $13K · Tuffin Paula filed 2d agoBETR ▼ sold $14K · Nicholas J. Calamari filed 2d agoFBK ▲ bought $716K · INGRAM ORRIN H II filed 2d agoFBK ▲ bought $821K · INGRAM ORRIN H II filed 2d agoBEN ▼ sold $5.0M · FRANKLIN TEMPLETON INC filed 2d agoNAD ▼ sold $338K · Robert Young L filed 3d agoWSBC ▼ sold $15K · Rep. Michael A. Rulli filed 4d agoGOOG ▼ sold $100K · Rep. Michael A. Rulli filed 4d agoWMT ▼ sold $100K · Rep. Jonathan L. Jackson filed 4d agoVSAT ▼ sold $100K · Rep. Jonathan L. Jackson filed 4d agoTYG ▼ sold $15K · Rep. Jonathan L. Jackson filed 4d agoGH ▲ bought $50K · Rep. Jonathan L. Jackson filed 4d agoEL ▲ bought $100K · Rep. Jonathan L. Jackson filed 4d agoDDOG ▲ bought $100K · Rep. Jonathan L. Jackson filed 4d agoCPRT ▼ sold $553K · Morefield Diane M filed 4d agoPTON ▼ sold $154K · Kirol Charles Peter filed 4d agoEME ▲ bought $1K · MCEVOY M KEVIN filed 4d agoEME ▲ bought $826 · MCEVOY M KEVIN filed 4d ago

Insider / CLOROX CO /DE/

Lee Esther

Director at CLOROX CO /DE/

Company
CLOROX CO /DE/
Ticker
CLX
First filing on record
January 5, 2026
Latest trade on record
December 31, 2025
SEC filings
EDGAR ↗

Lee Esther, Director at CLOROX CO /DE/, has disclosed 5 transactions in CLX since January 5, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed January 5, 2026, 5 days after the trade; 5 filings were late against the 2-business-day Form 4 deadline.

Last updated January 5, 2026 · Source: SEC EDGAR Form 4 filings

Transactions
5
Open-market buys
0
Sales
0
Avg. disclosure lag
152.0d

Trading in charts

Trade timeline

When does this person trade, how big, and in which direction? Every trade in the last 12 months.

Bought (above the line)Sold (below the line)Other transaction
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep

In the last 12 months Lee Esther reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.

What kind of transactions

Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.

Rows by Form 4 transaction code
CodeMeaningRowsSharesValue
AGrant or award52,178—
Rows by year of the trade
YearRowsBoughtSold
2025500

Transactions

Download CLX trades (CSV)152 rows · 48 KB · every filer in this ticker, this insider included · all downloads

SecuritySideTrade dateDisclosedLagSharesPriceValueFlagsSourceShare
CLXOther ADecember 31, 2025January 5, 20265d1,638——latederivativeForm 4 ↗
CLXOther ANovember 6, 2025January 5, 202660d162——latederivativeForm 4 ↗
CLXOther AAugust 29, 2025January 5, 2026129d144——latederivativeForm 4 ↗
CLXOther AMay 9, 2025January 5, 2026241d123——latederivativeForm 4 ↗
CLXOther AFebruary 14, 2025January 5, 2026325d111——latederivativeForm 4 ↗

Filings

FiledFormAccessionRowsStatusSource
January 5, 2026Form 40001225208-26-0001755publishedEDGAR ↗

Other insiders at CLOROX CO /DE/

Everyone on file, with contracts and lobbying under the company's name: CLOROX CO /DE/.

Guides for this page

Sources and method

Official sources behind this page
SourceFilingsRowsFirst filedNewest filedRead the originals
SEC EDGAR, Form 415January 5, 2026January 5, 2026Form 4 list on EDGAR

Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.

Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.

Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.